Breast Cancer Group

Weinkove, R, et al, Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance, Medical Journal of Australia (published online 1 June 2020)
"Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID‐19. Community transmission of COVID‐19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic."

The Australian Digital Health in Cancer Care Roadmap (published November 2019)
This Roadmap is intended to identify priorities for the development, implementation and use of digital health technologies in cancer care in Australia so that health systems can respond to priority needs identified that reflect best evidence and consumer and other stakeholder input. The Roadmap has been endorsed by COSA and other organisations listed on page 2.

Standard for Informed Financial Consent (published 2019, reviewed April 2020)
The Standard for Informed Financial Consent guides health professionals and practices to discuss the risks and benefits of treatment to include cost. The Standard was developed by Breast Cancer Network Australia, Cancer Council Australia, CanTeen and Prostate Cancer Foundation of Australia as a key component of delivering quality care. COSA along with other organisations listed on page 11 endorse the Standard for Informed Financial Consent.

This document is a joint position statement from COSA, the Human Genetics Society of Australasia (HGSA), the Royal College of Pathologists of Australasia (RCPA), and the Royal Australian College of General Practitioners (RACGP) on the role of single nucleotide polymorphisms (SNP) testing for personalised breast cancer risk prediction.

• • What is SNP testing?
  • The availability of SNP testing for breast cancer risk
  • Points to consider around SNP testing for breast cancer risk

Download